Cargando…

Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer

SIMPLE SUMMARY: Several chemotherapy drugs are approved for ovarian cancer treatment in the neo-adjuvant/adjuvant setting as well as following relapse. These include carboplatin, paclitaxel, doxorubicin, topotecan, PARP inhibitors (PARPi), and gemcitabine. However, except for PAPRi, there are no pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma Saha, Sweta, Gentles, Lucy, Bradbury, Alice, Brecht, Dominik, Robinson, Rebecca, O’Donnell, Rachel, Curtin, Nicola J., Drew, Yvette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003626/ https://www.ncbi.nlm.nih.gov/pubmed/33804647 http://dx.doi.org/10.3390/cancers13061420

Ejemplares similares

Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting
por: Bradbury, Alice, et al.
Publicado: (2020)

The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response
por: Bradbury, Alice, et al.
Publicado: (2022)

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor
por: Franklin, Miriam, et al.
Publicado: (2018)

Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types
por: Gentles, Lucy, et al.
Publicado: (2019)

Targeting the ATR-CHK1 Axis in Cancer Therapy
por: Rundle, Stuart, et al.
Publicado: (2017)

Lasting pathologic complete response to chemotherapy for ovarian cancer after receiving antimalarials for dermatomyositis
por: Cadena, Isabella, et al.
Publicado: (2018)

Targeting the DNA damage response for cancer therapy
por: Curtin, Nicola J.
Publicado: (2023)

Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer
por: Stefanou, Dimitra T., et al.
Publicado: (2015)

The ubiquitous role of ubiquitin in the DNA damage response
por: Al-Hakim, Abdallah, et al.
Publicado: (2010)

Correction: Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer
por: Stefanou, Dimitra T., et al.
Publicado: (2021)

Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer
por: O’Donnell, Timothy, et al.
Publicado: (2018)

The Plant DNA Damage Response: Signaling Pathways Leading to Growth Inhibition and Putative Role in Response to Stress Conditions
por: Nisa, Maher-Un, et al.
Publicado: (2019)

The development of PARP inhibitors in ovarian cancer: from bench to bedside
por: Drew, Yvette
Publicado: (2015)

Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy
por: Saha, Santu, et al.
Publicado: (2022)

Copper transport system and response to ovarian cancer chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma
por: Southgate, Harriet E. D., et al.
Publicado: (2020)

Ovarian damage from chemotherapy and current approaches to its protection
por: Spears, N, et al.
Publicado: (2019)

The Impact of Chemotherapy on the Ovaries: Molecular Aspects and the Prevention of Ovarian Damage
por: Sonigo, Charlotte, et al.
Publicado: (2019)

Genomic Consideration in Chemotherapy-Induced Ovarian Damage and Fertility Preservation
por: Kim, Seongmin, et al.
Publicado: (2021)

Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry
por: Vezzio-Vié, Nadia, et al.
Publicado: (2022)

Integrated genomics of ovarian xenograft tumor progression and chemotherapy response
por: Stuckey, Ashley, et al.
Publicado: (2011)

Enhancing Chemotherapy Response with Bmi-1 Silencing in Ovarian Cancer
por: Wang, Enfeng, et al.
Publicado: (2011)

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
por: Perroud, Herman Andrés, et al.
Publicado: (2017)

Chemotherapy induced DNA damage response: Convergence of drugs and pathways
por: Woods, Derek, et al.
Publicado: (2013)

Overexpression of eIF3a in Squamous Cell Carcinoma of the Oral Cavity and Its Putative Relation to Chemotherapy Response
por: Spilka, Rita, et al.
Publicado: (2012)

Protective effects of mangafodipir against chemotherapy-induced ovarian damage in mice
por: Qin, Ying, et al.
Publicado: (2018)

Molecular Mechanism and Prevention Strategy of Chemotherapy- and Radiotherapy-Induced Ovarian Damage
por: Kim, Seongmin, et al.
Publicado: (2021)

p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer
por: Ferrandina, G, et al.
Publicado: (1999)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer
por: Huang, Rui, et al.
Publicado: (2015)

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer
por: Alifrangis, C, et al.
Publicado: (2016)

Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response
por: Martín de la Fuente, Laura, et al.
Publicado: (2018)

Arsenic Disruption of DNA Damage Responses—Potential Role in Carcinogenesis and Chemotherapy
por: Muenyi, Clarisse S., et al.
Publicado: (2015)

Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer
por: Kubelac, Paul, et al.
Publicado: (2020)

Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma
por: Wong, Oscar G. W., et al.
Publicado: (2021)

The Role of Chemotherapy in Upper Tract Urothelial Carcinoma
por: O'Donnell, Peter H., et al.
Publicado: (2009)

The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and patient outcome
por: Walker, Thomas D. J., et al.
Publicado: (2023)

MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer
por: Simmer, Femke, et al.
Publicado: (2015)

The role of antimullerian hormone in assessing ovarian damage from chemotherapy, radiotherapy and surgery
por: Wong, Queenie Ho Yan, et al.
Publicado: (2018)

Response to letter by Campbell et al. regarding the results of the COSTICK trial
por: Smyth, Andrew, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_laql6bjfoh0nsacsk1nu0p0th6